ANTICANCER ACTIVITY OF POLYMERIC NANOPARTICLES CONTAINING ETOPOSIDE USING ALBINO RATS AS EXPERIMENTAL ANIMAL MODEL

Ayyappan T; Shanmugam S

doi:10.22159/ajpcr.2018.v11i12.28127

Authors

Ayyappan T Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur - 603 319, Kanchipuram, Tamil Nadu, India.
Shanmugam S Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur - 603 319, Kanchipuram, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i12.28127

Keywords:

Etoposide, Anticancer, Hepatocellular carcinoma, Diethylnitrosamine

Abstract

Objective: Etoposide is a potent anticancer drug and a major limiting factor that hinders therapeutic use as its high levels of systemic circulation often associated with various off-target effects, particularly cardiotoxicity. The present study focuses on the evaluation of the anticancer activity of optimized etoposide nanoparticles compared with marketed etoposide formulation in experimental animal models.

Methods: Albino rats (180â€“200 g) were used for the study. The anticancer effect of the formulated etoposide nanoparticles was evaluated by induction of hepatocellular carcinoma (HCC). The animals housed in cages and kept on a 12 h light/dark cycle. Following the acclimatization for 1 week, HCC will be induced in rats by adding 100 mg/L of diethylnitrosamine (DENA) in drinking water for 8 weeks. Drug treatment (etoposide [9 mg/kg] in 0.5 % carboxymethyl cellulose; p.o.) can be started at the end of 1 week after cancer induction and dose of 9 mg/kg of etoposide and lyophilized nanoparticles will be administered through oral route on 1, 7, 14, 21, and 28 days. Nanoformulations were evaluated in healthy rats, and anticancer activity was studied in DENA treated rats.

Results: The results showed that the polymeric nanoparticles containing etoposide was screened for its anticancer activity by counting the liver nodules of rats with hematoxylin and eosin stain when comparing control and etoposide-treated group.

Conclusion: The results of the study concluded that in rats treated with nanoformulations, the numbers of liver nodules were found to be significantly reduced.

Downloads

Download data is not yet available.

References

Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007;252:9-18.

Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 2012;9:2444-53.

McLeod HL, Evans WE. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv 1993;17:253-68.

Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994;12:2390-7.

Hande KR. Etoposide pharmacology. Semin Oncol 1992;19:3-9.

Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 1994;34 Suppl: S69-75.

Chellampillai B, Pawar AP. Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles. Eur J Drug Metab Pharmacokinet 2011;35:123-9.

Thiyagarajan A, Saravanabhavan S, Thangarasu V. Preparation and biopharmaceutical evaluation of novel polymeric nanoparticles containing etoposide for targeting the cancer cells. Turk J Pharm Sci 2018. (In Press).

Fonseca C, SimÃµes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002;83:273-86.

Sangeetha N, Kumaraguru AK. Antitumor effects and characterization of biosynthesized iron oxide nanoparticles using seaweeds of Gulf of Mannar. Int J Pharm Pharm Sci 2015;7:469-76.

Preethi R, Padma PR. Anticancer activity of silver nanobioconjugates synthesised from Piper betle leaves extract and its active compound eugenol. Int J Pharm Pharm Sci 2019;8:201-5.